Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$30.33 USD
-0.13 (-0.43%)
Updated May 31, 2024 04:00 PM ET
After-Market: $30.34 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Brokerage Reports
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 381 - 400 ( 720 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q1 Preview: Symphony Health Q1 EXPAREL Estimate Within 2% of Consensus-Reducing Our Q1 EXPAREL; Reiterate OUTPERFORM and $89 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of April 17
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences Upcoming Events for the Week of April 10.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
April and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Symphony Health Estimate for February EXPAREL Sales In-Line; Reiterate OUTPERFORM and $89 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
PILLAR Study at AAOS Meeting Well Received; Two New Tidbits Revealed
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of March 13
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
March and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q4/FY16 Update; We Anticipate Continued Sales Growth in 2017; Reiterate OUTPERFORM and $89 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of Feb 27
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Symphony Health Estimate for January EXPAREL Sales; Reiterate OUTPERFORM and $89 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb 20
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of Feb 13
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
February and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L